Acute myeloid leukemia 1 (AML1) belongs to a family of DNA-binding proteins highly conserved through evolution. AML1 regulates the expression of several hematopoietic genes and is essential for murine fetal liver hematopoiesis. We report here that the histone methyltransferase SUV39H1, a mammalian ortholog of the Drosophila melanogaster SU(VAR) 3-9, forms complex with AML1. SUV39H1 methylates lysine 9 of the histone protein H3 leading to the formation of the high-affinity binding site on chromatin for proteins of the heterochromatin protein 1 family (HP1). The interaction of AML1 with SUV39H1 requires the N-terminus of AML1 where the Runt domain is located. Binding of AML1 to SUV39H1 abrogates the transactivating and DNA-binding properties of AML1 and dissociates the net-like nuclear structure of AML1. It has been reported that AML1 is capable of interaction with histone acetyl transferases (CBP, p300, and MOZ) and with component of the histone deacetylase complex (Sin3), and that the interaction with these coregulators affects the strength of AML1 in promoter regulation. Our data suggest that other enzymes are also involved in gene regulation by AML1 activity by modulating the affinity of AML1 for DNA.
Introduction
Acute myeloid leukemia 1 (AML1) belongs to a family of highly homologous DNA-binding proteins, including also AML2 and AML3 that have specific patterns of expression and are conserved through evolution. Genetic studies in the mouse showed that in the developing murine embryo, AML1 is essential for liver hematopoiesis (Okuda et al., 1996; Wang et al., 1996) and regulates the expression of the hematopoietic genes interleukin 3 (IL-3), macrophage colony-stimulating factor (G-CSF), granulocyte macrophage colony-stimulating factor (GM-CSF), and myeloperoxidase (MPO) (for a recent review on AML1, see Speck and Gilliland, 2002) . In addition, AML1 has been implicated in the regulation of the cell cycle Cao et al., 1998) . Given these diverse and critical cellular functions, it is not surprising that AML1 is one of the most frequent targets of chromosomal lesions associated with human lymphoblastic and myeloid leukemia. In myeloid leukemia, AML1 is altered by inherited or acquired inactivating point mutations leading to haploinsufficiency (Barton and Nucifora, 2000; Osato et al., 2001; Michaud et al., 2002) . In B-and T-cell leukemia, the AML1 gene is amplified resulting in overexpression of the transcript (Mikhail et al., 2002) . AML1 interacts with tissue-specific transcription factors such as MYB, CCAAT/enhancer binding protein a (C/EBPa), and PU.1 as well as with several general transcription coregulators including the corepressors Sin3 and TLE and the histone acetyl transferase (HAT) coactivators CBP and p300. Quite recently, it was reported that the C-terminus of AML1 interacts with MOZ and that AML1 is acetylated in vitro by this enzyme (Kitabayashi et al., 2001) . Here, we have examined the ability of AML1 to interact with the histone methyltransferase (HMT) SUV39H1. This enzyme methylates lysine 9 of the histone protein H3 leading to the formation of the high-affinity binding site on chromatin for proteins of the heterochromatin protein 1 family (HP1) . Interaction of SUV39H1 has been reported for other proteins such as retinoblastoma protein (RB), histone deacetylases (HDAC1, 2 and 3), oncogenic orthophosphatase Sbf1, vertebrate Polycomb homologues HPC2/XPc2, and HP1 (Firestein et al., 2000; Vandel et al., 2001; Sewalt et al., 2002; Vaute et al., 2002; Yamamoto and Sonoda, 2003) .
We report that AML1 is methylated in vivo by a methyltransferase and that AML1 interacts with SUV39H1 both in vivo and in vitro. This interaction requires the N-terminus of AML1. Our data indicate that addition of SUV39H1 does not significantly increase the methylation of AML1, suggesting that the major role of AML1-SUV39H1 is probably not AML1 methylation. We further find that the interaction of AML1 with SUV39H1 decreases the in vitro affinity of AML1 to bind its DNA recognition site and abrogates the ability of AML1 to activate the macrophage colony-stimulating factor receptor (M-CSFR) promoter in reporter gene assays.
Results

AML1 Interacts with SUV39H1 both in vivo and in vitro
The HMT enzymes were first identified in yeast and the corresponding mammalian homologues were isolated later by screening mammalian cDNA libraries. These enzymes target either arginine or lysine residues for covalent addition of a methyl group. It is suggested that one of the major functions of HMT is the methylation of histones leading to a change in the configuration of the nucleosome (Birds and Wolffe, 1999; Cameron et al., 1999; Rea et al., 2000; Lachner et al., 2001; Noma et al., 2001; Maison et al., 2002; Peters et al., 2002) . SUV39H1 has been associated with methylation of lysine 9 of histone H3 (H3-K9) resulting in transcription repression Peters et al., 2001) . A limited number of proteins other than histones interact with SUV39H1 (Firestein et al., 2000; Vandel et al., 2001; Sewalt et al., 2002; Vaute et al., 2002) . To determine whether AML1 could have the ability to interact with SUV39H1, we used coimmunoprecipitation assay and Western blot analysis. It was shown by other investigators that normal cells and cell lines contain very low levels of endogenous SUV39H1 that are inadequate for protein-binding assays and therefore transient transfection is more useful for these assays (Sewalt et al., 2002) . Therefore, we transiently transfected 293 T cells with plasmids encoding epitope-tagged Flag-AML1 and Myc-SUV39H1 as described in Materials and methods. Two days after transfection, total cellular proteins were coimmunoprecipitated with anti-Myc antibody and separated by SDS-polyacrylamide gel electrophoresis (PAGE). Total cellular proteins were used in the same gel as control for protein expression. After transfer of the separated proteins to a PVDF membrane, the proteins were hybridized to anti-Flag antibody. The results show that full-length Flag-AML1 and Myc-SUV39H1 form a complex in vivo that can be physically isolated by antiMyc coimmunoprecipitation (Figure 1a, top) . This complex contains a band visualized with anti-Flag antibody that corresponds to Flag-AML1 in cells transfected with AML1, but not in cells transfected with the empty vector ( Figure 1a, lanes 1 and 2) . Western blot analysis of total cell lysates confirms the results (Figure 1a, lanes 3 and 4) . The expression of SUV39H1 in the co-immunoprecipitation reactions was confirmed by stripping the membrane followed by a second hybridization with anti-Myc antibody ( Figure 1a , bottom, lane 2). To further confirm the interaction between the two proteins, we carried out a reverse coimmunoprecipitation. The proteins were pulled down with agarose-tagged anti-Flag antibody and detected with anti-Myc antibody. The results (Figure 1b, top) showed that full-length AML1 interacts with SUV39H1 (lane 2, immunoprecipitated proteins; lane 5, total cellular proteins). No band was observed when AML1 was transfected in the cells without SUV39H1 (Figure 1b To further test the specificity of the interaction between AML1 and SUV39H1, we performed binding assay with in vitro translated AML1 and Myc-SUV39H1 proteins. To confirm the efficiency of in vitro translation, AML1 was labeled with To identify the region of AML1 that interacts with SUV39H1, we constructed a panel of HA-tagged or Flag-tagged deletion mutants (Figure 2a) . The distal boundary of each deletion was chosen based on functional or structural characteristics. Therefore, the longest deletion mutant, AML1-257, corresponds to the short normal AML1 form known as AML1a. It is known that SUV39H1 methylates lysine residues only. There are only nine lysine residues in AML1. The deletion mutant AML1-190 was chosen so that it contains all the lysine residues of AML1. The third deletion mutant, AML1-177, ends at the t(8; 21) chromosomal translocation breakpoint (Miyoshi et al., 1993) . We also constructed an N-terminus deletion of AML1 that does not contain any of the lysine residues. This region of AML1 (encoding amino acid (aa) 193-453) was cloned in frame to a nuclear localization signal to ensure the proper localization of the deletion mutant. Analysis of the results obtained with the C-terminus deletion mutants shows that SUV39H1 interacts with each one of them, suggesting that the interaction requires a region within the Runt domain (Figure 2b top, lanes 1, 2 and 3). To confirm the expression of SUV39H1 in the immunoprecipitation reaction, the membrane was stripped and hybridized to anti-Myc antibody (Figure 2b , bottom). SUV39H1 is detected in lanes 1-3, containing the deletion mutants, but not in lane 4 containing proteins isolated from mock-transfected cells. To determine whether there are additional interaction sites with SUV39H1 in the Cterminus region of AML1, we repeated the immunoprecipitation assays with the Runt-less AML1 mutant 193-453 (diagrammed in Figure 2a Figure 2c , top, lanes 7-9. To confirm the expression of AML1 in the coimmunoprecipitation reaction, the same blot was stripped and reprobed with anti-Flag antibody (Figure 2c , bottom). Altogether, therefore, these assays suggest that the C-terminus of AML1 is not required for interaction AML1 interacts with SUV39H1 and is methylated in vivo S Chakraborty et al with SUV39H1 and that it does not contain alternative interaction sites for SUV39H1.
SUV39H1 abrogates the M-CSFR promoter transactivation by AML1
We and others have shown that AML1 acts as a transcription activator in reporter gene assays. We previously showed that in reporter gene assays in NIH-3T3 cells, AML1 activates the M-CSFR promoter (Fears et al., 1997) . Therefore, to determine whether SUV39H1 affects the transactivation properties of AML1, we used NIH-3T3 cells in transient transfection assays. The cells were transiently transfected with the M-CSFR-luciferase plasmid for 24 h and treated as described in Material and methods. For normalization of the transfection efficiency, we used the pRL-TK plasmid encoding the Renilla luciferase gene. The results are shown in Figure 3 . The activation of the reporter gene in absence of AML1 is arbitrarily taken as 1 (Figure 3 , bars 1, 3 and 5). In NIH-3T3 cells, AML1 transactivate the M-CSFR promoter about two-three folds ( Figure 3 , bar 2). However, when SUV39H1 and AML1 are added in equimolar concentrations, the transactivation by AML1 is abrogated (Figure 3 , bar 4). To determine whether the AML1 activity is affected by the interaction between the proteins or by the methylase activity of SUV39H1, we repeated the same assays with a point mutant inactive SUV39H1 that can interact with AML1, but is incapable of histones methylation. When the point mutant is added in equimolar amount to AML1, AML1 loses the activation potential ( Figure 3, bar 6 ).
Binding of AML1 to SUV39H1 reduces the DNA affinity of AML1
It has been reported that binding of proteins to the Runt-domain can enhance the DNA-binding property of AML1. As we observed that binding of SUV39H1 abrogates AML1 gene activation, we asked whether SUV39H1 also affects the DNA affinity of AML1. To test this hypothesis, we performed electrophoretic mobility shift assay (EMSA) with a labeled DNA probe corresponding to the AML1-binding site of the M-CSFR promoter. For this assay, we used AML1 and SUV39H1 proteins that were translated in vitro with a commercial reticulocyte lysate. The efficiency of in vitro translation of the two proteins is very similar (Figure 1c and data not shown). The protein-DNA complexes were separated on nondenaturing polyacrylamide gels and the results are shown in Figure 4 . The patterns obtained Figure 4 , lanes 1 and 2, respectively. We obtained background bands with the reticulocyte lysate suggesting that proteins are present in the lysate that interact with the DNA probe. It should be noted that to avoid false results due to the lysate bands, the total amount of reticulocyte lysate in all lanes was maintained constant at 20 ml. As expected and shown by others, in vitro translated AML1 (10 ml) induced a strong shift in the migration rate of the probe and a strong band appeared (Figure 4, lane 3) . However, the addition of increasing amount of SUV39H1 (3, 6, and 10 ml) to the AML1-probe-binding reaction decreased the affinity of AML1 for the DNA probe. With equal volumes of SUV39H1 and AML1 (10 ml each), the band has almost disappeared and only the lysate background bands are visible (Figure 4, lane 6) . Thus, the results suggest that interaction of SUV39H1 with the DNA-binding domain of AML1 affects the DNA-binding property of AML1.
Detection of AML1 associated fragment by chromatin immunoprecipitation (ChIP) assay
Results of reporter gene assays showed that SUV39H1 downregulates AML1 activity. In order to investigate whether SUV39H1 alters the binding of Flag-AML1 to its target promoter, we carried out ChIP analysis using antibody against the Flag epitope of AML1. The primers used for semiquantitative PCR analysis flank a region of 204 bp in the M-CSFR sequence containing the AML1-binding site. After immunoprecipitation of sheared chromatin and PCR amplification of the genomic DNA as described in Materials and methods, the PCR products were separated by agarose gel electrophoresis and visualized (Figure 5a ). In absence of transfected Flag-AML1, there was no amplification of the M-CSFR promoter region (Figure 5a , lane 1). Lane 2 shows a PCR positive control using genomic DNA isolated from 293 T cells. Lanes 3-7 show the results obtained with different number of cycles for cells transfected with only AML1 and lanes 8-12 represent the results obtained when SUV39H1 was also added. As expected, when Flag-AML1 is added to the cells a PCR band appears (Figure 5a , lane 4, after 28 cycles) and becomes stronger by increasing the PCR cycles (lanes 5-7). However, when SUV39H1 was co-expressed with AML1, no band for the M-CSFR was detected after 28 cycles of amplification and the amplified product was observed after 32 cycles (Figure 5a, lanes 10-12) . To evaluate the efficiency of DNA transfection, we measured the expression of AML1 in cells transfected with AML1 or AML1 and SUV39H1 by Western blot analysis, using the same amount (10 mg) of protein.
The results (Figure 5b ) indicate that the expression of AML1 is lower in cells transfected with AML1 alone (lane 2) than with AML1 and SUV39H1 (lane 3). This strengthens our observation that more target DNA was chromatin immunoprecipitated with AML1 alone than with AML1 and SUV39H1. As expected, no FLAG-AML1 was detected in untransfected cells (Figure 5b , lane 1). These data confirm the results of the EMSA and further indicate that the interaction between SUV39H1 and AML1 reduces the binding affinity of AML1 to its target promoter.
Coexpression of SUV39H1 and AML1 dissociates the defined nuclear structure of AML1
Confocal microscopy analysis of mammalian cells showed that AML1 is a nuclear protein giving a netlike staining pattern consistent with that of many nuclear matrix proteins. This net-like pattern was observed by us and others (McNeil et al., 1999; Chakrabarti et al., 2000) . In contrast, SUV39H1 forms large discrete nuclear bodies (Firestein et al., 2000) . To determine the cellular localization pattern of SUV39H1 and whether the association between the two proteins alters their pattern of localization, we examined, by immunofluorescence microscopy, cells that were transiently transfected with SUV39H1 only, AML1 only, and with both plasmids. For these assays, we used transient transfection and epitope-tagged proteins because the monoclonal antibodies are much more suitable for immunofluorescence microscopy analysis. Figure 6 (a and b) shows the results of immunofluorescence microscopy analysis of cells transfected either with SUV39H1 only (panel a) or with AML1 only (panel b). We confirmed that in almost all cells AML1 had the fine net-like staining that was previously observed and AML1 interacts with SUV39H1 and is methylated in vivo S Chakraborty et al reported by others. We also found that in about 15-20% of the nuclei, SUV39H1 was concentrated in a small number of large speckles (3-10). In the remaining cells, SUV39H1 was still nuclear but diffused (not shown). However, when the two proteins were coexpressed in the cell, the net-like structure and the large speckles disappeared and all the nuclei had the same diffused staining (Figure 6 , panel c-e). These results would suggest that the interaction of AML1 with SUV39H1 leads to the complete disruption of the net-like structure that we and others noted in almost all the cells transfected with AML1 only (Figure 6b ).
AML1 is methylated in vivo
To determine whether AML1 is methylated, we transfected 293 T cells with Flag-tagged AML1. Immunoprecipitated AML1 was resolved in an SDS-PAGE and methylated-lysine-specific antiserum was used to identify methylated proteins. The results showed that the antibody identified a band in the lane containing the immunoprecipitated products of AML1-transfected cells (Figure 7a (Figure 7b right side, lanes 2 and 3). The level of expression of AML1 in the immunoprecipitated products is comparable. These results would indicate either that the methylase that modifies AML1 is probably not SUV39H1 or that additional factors present in limiting amount in the cell are required for efficient methylation of AML1.
Discussion
It has been reported that the leukemia-associated transcription activator AML1 interacts with several coactivators, including CBP/p300 and MOZ, and that is acetylated in vitro by MOZ. These coregulators are involved in the regulation of chromatin structure and gene activation. Here, we report that AML1 interacts with the histone lysine methyltransferase SUV39H1, associated with gene silencing, and that AML1 is methylated in vivo by a protein methylase. We found that the AML1 region required for interaction with SUV39H1 is the Runt domain that also interacts with tissue-specific transcription factors and with CBFb. AML1 belongs to a family of evolutionarily conserved proteins that contain a limited number of lysine residues located within and near the Runt domain. It is, therefore, very likely that the methylation of lysine residues is a biological signal for the function of these proteins. We also find that the interaction of AML1 with SUV39H1 leads to very low affinity for the DNA. These results, obtained with three separate systems, are surprising because AML1 is a well-known transcription activator of several genes. We and others showed that AML1 activates the M-CSFR promoter in reporter gene assays (Rhoades et al., 1996; Fears et al., 1997) and that MOZ and p300 increase the transactivating strength of AML1 (Kitabayashi et al., 1998 (Kitabayashi et al., , 2001 ). However, here we also show that SUV39H1 abrogates the transactivation of the M-CSFR promoter by AML1. There are several potential mechanisms by which SUV39H1 could affect the transactivation of a promoter by AML1. The classic mechanism is the recruitment of SUV39H1 to a specific promoter leading to promoter silencing by histone methylation. However whereas our data do not exclude this model, the results of reporter gene assays, ChIP and EMSA, strongly suggest that the association between AML1 and SUV39H1 leads to the dissociation of AML1 from the promoter DNA. During the last few years, there have been several reports showing that the acetylation of lysine residues by HAT enzymes is not restricted to histones but is a frequent modification of transcription factors. Acetylation changes several functions of a protein and affects the DNA affinity, the cellular localization of transcription factors and the regulation of the cell cycle (Gu and Roeder, 1997; Imhof et al., 1997; Boyes et al., 1998; Zhang and Bieker, 1998; Hung et al., 1999; MartinezBalbas et al., 2000; Marzio et al., 2000; Zhang et al., 2000; Chan et al., 2001; Ferreira et al., 2001; Polanowska et al., 2001; Wang et al., 2001) . Methylation, like acetylation and phosphorylation, represents a signal to perform a specific function and it is likely that in addition to histones, several transcription factors can be methylated. The methylation of AML1 is the first report of factor methylation by a protein methyltransferase. We did not observe a significant increase in AML1 methylation by addition of increasing amounts of SUV39H1. This would suggest either that the methyltransferase required for AML1 modification is not SUV39H1, or that the methylation of AML1 is very short lived, or that methylation requires another factor present in limiting amounts in the cell. However, given the limited number of lysine residues and their critical location in the DNA-and factor-binding domain, it is likely that methylation regulates the interaction of AML1 with either the DNA and/or with specific factors. Finally, another mechanism by which a methylase can regulate AML1 activity is by methylation of AML1 leading to alternative interaction partners or to different nuclear localization. We find that the association of AML1 with SUV39H1 not only affects the DNAbinding property of AML1, but also abrogates the punctuated staining described for other nuclear matrix proteins.
Materials and methods
Construction of AML1 deletion mutants and plasmids used in this study
The HA epitope was amplified by PCR from an appropriate template and was cloned into the NcoI/PstI site of the pCMV vector (Invitrogen/Life Technologies, Inc). The full-length and mutants AML1 cDNAs were obtained by PCR technique and were cloned into the HA-tagged pCMV vector. The AML1 deletion mutants were generated by using the unique HindIII site in the Runt domain and PCR adapter primers containing HindIII (upstream primer) or a stop codon and a XhoI site (downstream primer). The Runt DNA-binding region of AML1 contains the nuclear localization signal (NLS) of AML1. Therefore, the Runt-less construct (starting from aa 193 to the end) was cloned in a derivative of pCMV-Flag that has the NLS of the plasmid pCMV-Myc-Nuc. For in vitro transcription and translation, we used AML1 cloned in pBluescript (SK-) vector (Stratagene). The plasmids SUV39H1-(Myc) 3 and dominant-negative SUV39H1-(Myc) 3 were gifted by Dr T Jenuwein, Austria.
Cell culture
The adherent cell lines NIH-3T3, 293, and 293 T used in this study were cultured in Dulbecco's modified minimum essential medium supplemented with 10% newborn calf serum (Life Technologies, Inc.).
Coimmunoprecipitation and Western blot analysis
293 T cells were used for transfection assays by the calcium phosphate method (Invitrogen/Life Technologies, Inc). The cells were harvested 48 h after transfection and treated as described (Chakraborty et al., 2001) . The Flag-tagged AML1 or Myc-tagged SUV39H1 was immunoprecipitated by incubation with commercially available antibody-coupled M2 agarose affinity gel (Sigma) or c-Myc antibody (Santa Cruz) as suggested by the manufacturer. Protein separation and transfer were carried out as described (Chakraborty et al., 2001) . Protein bands were identified with commercially available monoclonal antibody to the Flag epitope (Sigma) and the HA epitope (Roche), c-Myc (Cell Signaling Technology), polyclonal methyl lysine antibody (Abcam Limited, UK), and with rabbit polyclonal SUV39H1 antibody (Cell Signaling Technology).
In vitro binding assay
The in vitro translation of Myc-SUV39H1 and AML1 was carried out according to manufacture's instruction using reticulocyte lysate systems (Promega) in the presence or absence of [
35 S]methionine (Amersham). In vitro translated [ 35 S] methionine labeled AML1 was mixed with in vitro AML1 interacts with SUV39H1 and is methylated in vivo S Chakraborty et al translated unlabeled SUV39H1 and incubated at 371C for 30 min. The reaction mixtures of AML1 or SUV39H1 or AML1 and SUV39H1 were diluted to 250 ml with HND buffer and immunoprecipitated with anti-Myc antibody as described in Huang et al. (1993) . The products were separated in an 8% SDS-PAGE, dried, and autoradiographed.
Reporter gene studies
The M-CSFR promoter linked to the luciferase reporter gene (pM-CSFR-luc) contains the region À416 to þ 71 of the human M-CSFR promoter and was described (Rhoades et al., 1996) . This promoter is activated by AML1. For normalization of transfection efficiency, we used pRL-TK plasmid (Promega) that expresses Renilla luciferase. The experiment was repeated three times. . The binding assays were carried out for 30 min at 251C in a total volume of 30 ml in 20 mM HEPES pH 7.6 with 10% glycerol, 2 mm EDTA, 1 mm DTT, and poly-dI:dC (1 mg/reaction).
32 P-endlabeled probe (0.2 pm/reaction) was added after 10 min and incubation was continued for additional 20 min. The samples were loaded on 0.5 Â Tris-borate-EDTA nondenaturing 6% polyacrylamide gel, electrophoresed at 100 V for 3 h at 41C, and autoradiographed overnight.
Chromatin-immunoprecipitation assay
Chromatin immunoprecipitation assay was done essentially as described by El-Osta and Wolfer (2001) . Briefly, 5 Â 10 6 293 T cells were transfected with plasmids encoding for Flag-AML1 or Flag-AML1 and SUV39H1. After 48 h, cells were crosslinked with 0.8% formaldehyde for 10 min at room temperature. Cell nuclei were lysed and the lysate was sonicated five times for 10 s using 'digital sonifer' sonicator (Branson) to obtain average DNA fragment size of 500-1000 bases. It was appropriately diluted and precleared with 60 ml of protein G agarose. Each sample was divided in two halves. Immunoprecipitation was carried out overnight using 10 ml of anti-Flag (M2) antibody followed by 40 ml protein G agarose slurry with one set of sample and the other half was processed without the antibody. Beads were washed, eluted and the crosslinking of protein/DNA complexes was reversed by heating at 651C for 8 h. DNA was extracted with phenol : chloroform and precipitated. Then the samples were subjected to PCR using primers 5 0 -atggctttagaagggccccaaac-3 0 (sense) and 5 0 -cttgttttcctcttcctcctccttggg-3 0 (antisense), which are designed to amplify 204 bp region encompassing the promoter region of M-CSFR gene, which is a target for AML1. The condition for PCR was 951C for 5 min, 951C for 1 min, 641C for 30 s, 721C for 30 s for 24, 28, 32, 36 and 40 cycles. PCR products were analysed on a 2% agarose gel and 100 bp Gene Ruler (MBI, Fermentas) was used as a molecular marker.
Immunofluorescence microscopy analysis 293 cells were cultured on 0.1% gelatin-treated coverslips and transfected with plasmids encoding AML1 (Flag-or HAtagged), or Myc-tagged SUV39H1, or both plasmids using Nova-fector reagent (Venn Nova, Inc.) according to the manufacturer's instruction. After 24 h, the cells were processed as described (Chakraborty et al., 2001) . Mouse anti-Myc monoclonal antibody (Santa Cruz) and rat anti-HA monoclonal antibody (Roche) were used as primary antibody at a dilution of 1 : 2000 for 1 h. After washing with PBS, the cells were stained with rabbit anti-mouse fluorescein isothiocyanate 488 and goat anti-rat Texas-red 594 (Molecular Probe) at a dilution of 1 : 2000 for 1 h. The cells were washed and treated with a prolonged anti-fading medium (Molecular Probe), and the proteins were visualized using a fluorescence microscope (Zeiss Inc.).
